Orforglipron vs Tirzepatide
How they differ
- FDA status, the same for both (FDA-approved). Orforglipron: FDA-approved as Foundayo for weight reduction in adults.1,2 Tirzepatide: FDA-approved as Mounjaro and Zepbound.3,4,5
Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.
Side by side
| Topic | Orforglipron | Tirzepatide |
|---|---|---|
| What it is | Not a peptide: a small molecule often looked up alongside peptides6 A synthetic small-molecule, nonpeptide agonist of the GLP-1 receptor, the active ingredient of Foundayo.2,6 | A GIP receptor and GLP-1 receptor agonist. The Zepbound label states that it selectively binds to and activates both receptors.3 |
| FDA status | FDA-approved FDA-approved as Foundayo for weight reduction in adults1,2 FDA-approved. Drugs@FDA lists Foundayo with an original approval date of April 1, 2026. The label has a boxed warning about the risk of thyroid C-cell tumors.1,2 | FDA-approved FDA-approved as Mounjaro and Zepbound3,4,5 FDA-approved. Drugs@FDA lists Mounjaro (first approved May 13, 2022) and Zepbound (November 8, 2023). The Zepbound label carries a boxed warning about thyroid C-cell tumors seen in rats.3,4,5 |
| HHS compounding policy, October 30, 2026 | Not among the six peptides the policy lists.7 | Not among the six peptides the policy lists.7 |
| FDA compounding safety-risk page | Not addressed in this profile’s sources. | Not addressed in this profile’s sources. |
| Kinds of studies cited |
|
|
| Records collected | 25 ClinicalTrials.gov records and 7 PubMed records collected | 108 ClinicalTrials.gov records and 75 PubMed records collected |
| Area of study | ||
| Latest dated events |
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Citations
Sources
Numbered markers in the text point here. Each link opens the original public record.
- 1Drugs@FDA: FOUNDAYO (orforglipron calcium), NDA 220934 · original approval April 1, 2026 ↗
U.S. Food and Drug Administration · Official source · Source checked November 16, 2026
- 2FOUNDAYO (orforglipron) tablet, film coated · SPL version 10 · published 2026-08-13 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 16, 2026
- 3ZEPBOUND (tirzepatide) injection · SPL version 40 · published 2026-09-02 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked September 15, 2026
- 4Drugs@FDA application NDA215866 · original submission status AP · 2022-05-13 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 5Drugs@FDA application NDA217806 · original submission status AP · 2023-11-08 · dataset 2026-08-13 ↗
Drugs@FDA via openFDA · Official source · Source checked August 14, 2026
- 6Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (2025) · PMID 40960239 ↗
The New England Journal of Medicine · Official source · Source checked November 16, 2026
- 7HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 8Mounjaro (tirzepatide): NDA 215866 supplements S-044 and S-045 approval letter, August 27, 2026 ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 9Zepbound (tirzepatide): NDA 217806 supplement S-041 corrected approval letter, effective August 26, 2026 ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 10FDA’s concerns with unapproved GLP-1 drugs used for weight loss · content current as of October 1, 2026 ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026